Abstract
Background
The role of lymphadenectomy in adrenocortical carcinoma resection is controversial. Therefore, we conducted a population-based study to assess the association between positive lymph nodes (LN) and survival.
Methods
The Surveillance, Epidemiology, and End Results set of cancer registries were utilized. The associations between positive lymph nodes and tumor size, grade and laterality were assessed. Cancer specific survival (CSS) trends and factors affecting survival were analyzed.
Results
A total of 2170 adult patients were identified; 60% underwent resection. Among those resected, LN were examined in 23% and were positive in 25% of patients with LN examined. Patients with positive LN tended to have smaller tumors compared to those with negative LN (12 ± 5 vs 15 ± 11 cm, p = 0.02). The rate of positive LN was higher in right ACC, p = 0.03. Median overall CSS was 21 months, with significant differences between resection (42 months) and no resection (4 months), p < 0.01. Median CSS did not change over time when comparing ACC patients who underwent surgery before 2000, 2000–2009, and 2010–2016. On multivariable analysis including resection group, advanced age, grades III and IV, regional and distant stage, in addition to positive LN were associated with worse survival, p < 0.05.
Conclusion
Lymphadenectomy is infrequently performed during ACC resection, and when performed, regional LN involvement tends to be associated with worse survival. Neoplasm size and grade were not associated with LN involvement and therefore, do not inform lymphadenectomy need. Further studies are needed to assess the indications for, and value of lymphadenectomy in ACC.
Similar content being viewed by others
References
Sada A, Asaad M, Bews KA, et al (2020) Comparison between functional and non-functional adrenocortical carcinoma. Surgery 167:216–223
Dickson PV, Kim L, Yen TW et al (2018) Evaluation, staging, and surgical management for adrenocortical carcinoma: an update from the SSO Endocrine and Head and Neck Disease Site Working Group. Ann Surg Oncol 25:3460–3468
Sharma E, Dahal S, Sharma P et al (2018) The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res 10:636
Dickson PV, Kim L, Yen TW et al (2018) Adjuvant and neoadjuvant therapy, treatment for advanced disease, and genetic considerations for adrenocortical carcinoma: an update from the SSO Endocrine and Head and Neck Disease Site Working Group. Ann Surg Oncol 25:3453–3459
Laan DV, Thiels CA, Glasgow A et al (2017) Adrenocortical carcinoma with inferior vena cava tumor thrombus. Surgery 161:240–248
Dy BM, Strajina V, Cayo AK et al (2015) Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol 22:146–151
Reibetanz J, Jurowich C, Erdogan I et al (2012) Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 255:363–369
Gerry JM, Tran TB, Postlewait LM et al (2016) Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit? Ann Surg Oncol 23:708–713
Miller BS, Doherty GM (2013) Regional lymphadenectomy for adrenocortical carcinoma. Ann Surg 257:e13–e14
Gaujoux S, Brennan MF (2012) Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery 152:123–132
List of the surveillance, epidemiology, and end results (SEER) program registreies. https://seer.cancer.gov/registries/list.html. Accessed on 16 Oct 2019
Review of Staging Systems. Available at https://training.seer.cancer.gov/collaborative/intro/systems_review.html. Accessed on 16 Oct 2019
Nilubol N, Patel D, Kebebew E (2016) Does lymphadenectomy improve survival in patients with adrenocortical carcinoma? A population-based study. World J Surg 40:697–705
Tran TB, Liou D, Menon VG et al (2013) Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis. Am Surg 79:1115–1118
Acknowledgements
This publication was made possible by CTSA Grant Number UL1 TR002377 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.
Author information
Authors and Affiliations
Contributions
Study conception and design: AS, AG, EH, TM. Acquisition of data: AS, AG. Analysis and interpretation of data: AS, AG, EH, TM, GT, BD, ML. Drafting of manuscript: AS, AG, EH, TM, GT, BD, ML. Critical Revision of manuscript: AS, AG, EH, TM, GT, BD, ML.
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix
Appendix
See Table 4.
Rights and permissions
About this article
Cite this article
Sada, A., Glasgow, A.E., Lyden, M.L. et al. Positive Lymph Nodes in Adrenocortical Carcinoma: What Does It Mean?. World J Surg 45, 188–194 (2021). https://doi.org/10.1007/s00268-020-05801-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-020-05801-x